Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain volatile
Thu, 13 Sep 01:30 pm

Indian share markets shed early gains and fluctuated on either side of the dotted line in the post-noon trading session. Majority of the sectoral indices are trading negative with pharma, realty and metal stocks leading the pack of losers. Oil and gas, PSU and FMCG stocks are among the gainers.

BSE-Sensex is down 16 points and NSE-Nifty is trading down 7 points. BSE Mid Cap is marginally down whereas BSE Small Cap index is trading flat. The rupee is trading at 55.4 to the US dollar.

Majority of the Indian pharma stocks are trading negative with Lupin and Orchid Chemicals being the biggest losers. Panacea Biotech and IPCA Labs are among the few stocks trading in the green. As per a leading financial daily, Aurobindo Pharma has won US Food and Drug Administration (USFDA) approval to sell generic version of anti-depressant drug Lexapro in the US markets. The company has bagged approvals for the escitalopram oxalate tablets in 5 mg, 10 mg and 20 mg strengths. According to IMS, Lexapro has a market size of US$ 2.8 bn. The company will be manufacturing the drug in the Unit III formulations facility in Hyderabad. Aurobindo Pharma has a total of 158 abbreviated new drug applications (ANDA) approvals from USFDA so far out of which 133 are final approvals. The stock is marginally up.

Most of the PSU banking stocks are trading negative with Union Bank and Indian Bank being the biggest losers. A leading business daily has reported India's largest bank State Bank of India (SBI) is looking at aggressively expanding its work force over the next one year. The bank is planning to add 20,000 personnel across both the officer and clerical cadres, which would increase its work force by 10%. As of June 2012, the bank had about 214,000 people on its pay roll. It is believed that SBI is targeting to open 1,200 branches this year. As such, a majority part of the staff being hired is for the same. In FY11 and FY12, the average employee per branch stood at 16 and 15 respectively. Also, this strong hiring plan is aimed towards readying itself for the future given that about 35 to 40% of the staff is expected to retire within a period of five years (across all levels).

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain volatile". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.